trending Market Intelligence /marketintelligence/en/news-insights/trending/mhwc4krc6z6nubgm5wcq0q2 content esgSubNav
In This List

US FDA accepts resubmission of Coherus application for Neulasta biosimilar

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


US FDA accepts resubmission of Coherus application for Neulasta biosimilar

The U.S. Food and Drug Administration accepted the resubmission of the biologics license application for Coherus Biosciences Inc.'s biosimilar of Amgen Inc.'s Neulasta.

A biosimilar is a biological medicine that is highly similar to and has no clinically meaningful differences from an existing FDA-approved brand-name biologic medicine.

The FDA previously rejected the company's application for CHS-1701 and asked Coherus to reanalyze samples from a subset of patients for immunogenecity and sought additional manufacturing related process information.

Immunogenecity refers to the ability of a drug or vaccine to stir a response from the patient's immune system.

The agency expects to take an action on the application by Nov. 3.